Clinical Study on Wuling Powder in Treating Metabolic Syndrome of Spleen Deficiency and Dampness

Launched by JIANGSU FAMOUS MEDICAL TECHNOLOGY CO., LTD. · Mar 22, 2021

Keywords

ClinConnect Summary

The research purpose of this project is to observe the effectiveness and safety of Wulingsan single decoction granules compared with traditional powder, co-decoction granules and analogues in the treatment of metabolic syndrome in combination with conventional therapies. ; Compared with Wulingsan traditional powder and co-decoction granule group, observe the effectiveness and safety of traditional powder combined with conventional therapy in the treatment of metabolic syndrome. The trial adopts a randomized, partially double-blind, controlled, multi-center clinical research method. A total ...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Patients who meet the diagnostic criteria of metabolic syndrome;
• • 2. TCM syndrome differentiation of spleen deficiency and dampness patients;
• • 3. Patients with phlegm-dampness constitution score\>30;
• • 4. Patients aged 18 to 70 years;
• • 5. Patients who have signed informed consent and are highly compliant.
• Exclusion Criteria:
• • 1. Patients with hypertension, hyperglycemia, and hyperlipidemia caused by secondary metabolic syndrome (disease, drugs, surgery, etc.);
• • 2. Patients with severe primary diseases such as heart, liver, kidney, lung, brain, endocrine, hematopoietic system in the past or at the time of enrollment;
• • 3. Those who are confirmed to have acute coronary syndrome, malignant arrhythmia, and other serious heart diseases;
• • 4. Patients with co-infection, malignant tumors or mental illness;
• • 5. Patients with Cushing syndrome;
• • 6. Patients with allergies or allergies to this drug;
• • 7. Pregnant or breastfeeding women;
• • 8. Those who have adjusted hypoglycemic, lipid-lowering, antihypertensive drugs or taking weight-loss drugs within 1 month before enrollment.